With advances in surgical techniques and perioperative care, hepatic resection for hepatocellular carcinoma (HCC) can be performed with a low hospital mortality rate, even in patients with chronic liver disease.
multinodular HCC (MNHCC) is less well-defined. The presence of multiple tumors has been shown to be one of the most significant independent factors to influence cumulative survival rates in patients with HCC who are undergoing hepatic resection. [9] [10] [11] [12] As a result of multicentric carcinogenesis or intrahepatic metastasis, MNHCC may benefit from palliation with local ablative treatment or chemoembolization rather than from hepatic resection, 3 but there are few clinical studies to validate this recommendation.
Although liver transplantation provides an alternative curative treatment option for MNHCC with size ≤ 5 cm in diameter and tumor number < 3, 13, 14 its application is limited by the shortage of organs in both Eastern and Western countries. Therefore, hepatic resection is still the mainstay of curative treatment for MNHCC, and surgical resection should be considered for all noncirrhotic patients or those with well-compensated Child-Pugh class A cirrhosis, without evidence of portal hypertension once they are free from extrahepatic spread. 15 The objective of the present study was to evaluate the long-term survival of patients with hepatic resection for MNHCC. We also examined nonsurgical multidisciplinary therapy during the same period for comparison, in the hope that it may help us to select a subgroup of patients with MNHCC who will benefit most from aggressive surgical intervention.
Patients and Methods
We reviewed the charts of 599 patients who had undergone hepatic resection for HCC in the Department of Surgery, Veterans General Hospital, Kaohsiung, Taiwan, during the 15-year period between October 1990 and June 2006. There were 16 surgical deaths (2.7%). Forty-nine patients were excluded from the study for loss to follow-up within 12 months after operation. In the remaining 537 patients, 425 had a single tumor, while 112 had MNHCC. The tumors were evaluated preoperatively by ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI) and hepatic arteriography, if indicated. In all patients, serum levels of α-fetoprotein (AFP), hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCVAb) were determined, and conventional liver function tests and the indocyanine green (ICG) clearance test were performed. Couinaud's liver segmentation was used to express tumor location and extent of hepatectomy. 16 Intraoperative ultrasonography was performed routinely to detect tumor nodules in the contralateral lobe, invasion of the tumor into the major blood vessels, and to mark the line of parenchymal transection on the liver surface to obtain an optimal tumor-free margin.
The classification of MNHCC was as follows: type A, multiple nodules that were close to each other and involved one or two adjoining segments; type B, large tumor with satellite nodules that involved three or more segments; type C, three or fewer nodules that were scattered in remote segments; and type D, more than three separate tumors (Figure 1 ). Type A tumors could be removed in one block. Type B-D tumors could be removed in one block with lobectomy or extended hepatectomy, if the tumors were confined to one side of the liver; otherwise multiple-site resection was employed. To determine the prognostic factors of hepatectomy for MNHCC, the clinicopathologic and biological variables of the 112 patients were analyzed. Those with tumors that were removed in one block and those that needed multiple-site hepatic resection were compared.
To investigate the efficacy of hepatectomy for MNHCC, we also looked at the database of 874 patients who had undergone nonsurgical multidisciplinary therapy for HCC during the same period. The detection of HCC was initially carried out with abdominal ultrasonography and spiral CT, MRI with contrast enhancement, or angiography with lipiodol injection. Follow-up CT was used for accurate diagnosis of MNHCC. There were 319 (36.5%) patients, of whom 178 underwent image-guided percutaneous needle biopsy for pathologic tissue investigation. To compare liver function, we enrolled 110 patients who had serum albumin > 3.5 g/dL and total bilirubin < 2.0 mg/ dL, who had been followed for at least 12 months after treatment. The choice of treatment modality was as follows. Generally, percutaneous acetic acid injection (PAI) or radiofrequency ablation (RFA) was used for ≤ 3 liver tumors and tumor size < 3 cm. Transcatheter arterial embolization (TAE) was used for tumors with well-enhanced contrast in imaging studies. Hepatic arterial infusion (HAI) was used for those with > 4 tumors and those with poor response to TAE. The methods of PAI, TAE and HAI were as described in previous studies. 17 Post-treatment follow-up was done with conventional liver function tests, serum AFP level, and abdominal ultrasonography at intervals of 2-3 months. CT was performed every 6 months, and ultrasonography in those who had suspected lesions. Chest roentgenography, whole-body bone scan or other imaging studies were undertaken if indicated, to detect possible recurrence. For those with liver recurrence, further hepatectomy was considered for the surgical group if liver functional reserve was adequate. Otherwise, the treatments were as described for nonsurgical multidisciplinary treatment.
The 
Clinicopathologic analysis of patients undergoing hepatectomy for MNHCC
The clinical features and types of hepatic resection performed are summarized in Table 1 . Of the 112 patients, recurrence of HCC was detected in 93 (88.8%), with a median disease-free survival period of 11 months (range, 2-147 months). Extrahepatic recurrence occurred in 27 patients (24.3%), including lung (12 patients), bone (6 patients), lymph nodes (6 patients), intra-abdominal seeding (5 patients), adrenal gland (3 patients), and brain (2 patients). The 1-, 3-and 5-year diseasefree survival rates were 45.7%, 29.2% and 18.4%, respectively. The results of hepatectomy are shown in Table 2 . The overall cumulative survival rates at 1, 3 and 5 years were 86.1%, 55.5% and 29.9%, respectively ( Figure 2 ). The median overall survival period was 47.0 months.
Treatment for recurrence
Of the 93 patients with recurrence, 13 underwent second hepatectomy and one a third hepatectomy. Twenty-five patients underwent local ablative therapy, including 44 sessions of PAI for 13 patients, and 25 sessions of RFA for 16 patients. Fifty-two patients underwent a total of 157 TAE procedures, with an average of three procedures per patient (1-12 procedures). Twenty-six patients underwent a total of 65 courses of HAI. Twentyone patients did not receive treatment of any kind. Seven patients were free from disease after multidisciplinary therapy for recurrence. invasion and multiple-site resection. The type of multinodularity was also found to influence prognosis. Those with nodules that were close to each other and that involved one or two adjoining segments (type A) had better survival than the other three types. By multivariate analysis, only multiple-site resection was an independent unfavorable prognostic factor that affected longterm survival (Table 4) .
Prognostic factors for survival
Resection margin (mm) 0.097 ≥ 10 59 46 13 < 10 53 51 36 Total tumor size (cm) 0.010* > 5 7 9 3 8 2 2 ≤ 5 3 3 7 4 3 8 Largest tumor size (cm) 0.006* > 5 5 8 3 2 2 2 ≤ 5 5 4 6 5 3 3 Type of multinodularity 0.020 A 4 8 6 4 3 6 B 2 1 2 4 1 9 C 2 9 4 0 1 2 D 1 4 5 1 3 3 Tumor number 0.024* > 3 4 8 3 7 2 3 ≤ 3 6 4 5 7 3
Comparison between hepatectomy and nonsurgical treatment
The overall cumulative survival rates for the 110 patients with serum albumin level ≥ 3.5 g/dL and total bilirubin level < 2 mg/dL in the nonsurgical group at 1, 3 and 5 years were 68.2%, 24.7% and 7.9%, respectively. The median overall survival period was 20 months, which was significantly shorter than that in the surgical group (47 months). We further investigated the efficacy of hepatectomy for those with tumor number ≤ 3 and largest tumor size ≤ 5 cm. There were 47 patients enrolled in the nonsurgical group and 38 in the surgical group. The clinical features are summarized in Table 5 . There was no significant difference in the rate of hepatitis B or C infection. The number of patients with elevated serum AFP, alanine aminotransferase and aspartate aminotransferase was not significantly different between the two groups. The proportion of type A multinodularity and percentage with bilobar involvement in the two groups were comparable. Among the 47 patients in the nonsurgical group, 44 underwent 188 sessions of TAE, 27 underwent 91 sessions of PAI, six underwent 11 sessions of RFA, and six underwent eight courses of HAI. Of the 38 patients in the hepatectomy group, four had no recurrence. Of the remaining 34 patients with recurrence, 22 underwent 85 sessions of TAE, six underwent 28 sessions of PAI, six underwent eight sessions of RFA, and seven underwent 13 courses of HAI.
There were six patients with extrahepatic metastasis in the nonsurgical group and five with extrahepatic recurrence in the hepatectomy group. Among the nonsurgical patients, 10 were still alive (3 had no evidence of disease and 7 were alive with disease), three patients died of complications associated with liver cirrhosis (gastrointestinal bleeding, spontaneous bacterial peritonitis and hypoglycemia, respectively), and the remaining 35 patients died of the disease. Among the hepatectomy group, seven had no evidence of disease and two were alive with disease. The overall cumulative 1-, 3-and 5-year survival rates in the hepatectomy group were 94.6%, 66.8% and 26.2%, respectively, with a median survival of 49 months. The result was significantly better than in the nonsurgical group, in which the cumulative 1-, 3-and 5-year survival rates were 87.5%, 42.1% and 22.6%, respectively, with a median survival of 30 months (p = 0.0327) (Figure 3) . However, for those with tumor number ≤ 3 and tumor size ≤ 5 cm, 22 patients who underwent multiple-site hepatic resection showed no survival advantage against the 47 patients who received nonsurgical multidisciplinary therapy. In contrast, the group of 16 patients who underwent one-block resection for MNHCC had significantly better survival (p = 0.0016) (Figure 4 ).
Discussion
The prognosis of HCC is generally poor. Partial hepatectomy remains the best hope for a cure but is suitable for only 9-27% of patients. 16 One of the major causes of such a low resectability rate is the presence of significant background cirrhosis. The other possible cause is the high incidence of tumor multiplicity, because patients with multiple tumors have a poorer outcome compared with those with a solitary tumor. [9] [10] [11] This has also been demonstrated in the present study, which shows that survival of patients with MNHCC 0  12  24  36  48  60  72  84  96  108  120  132  144  156  168  180  192 0  12  24  36  48  60  72  84  96  108  120  132  144  156  168  180  192 is significantly shorter than survival of patients with single HCC. However, some still perform aggressive surgical intervention and try to establish selection criteria for those patients who would benefit from hepatectomy. This issue has been addressed by dividing multiple HCCs into primary tumors with intrahepatic metastasis (IM) and synchronous multicentric tumors, and advocating that synchronous multicentric HCCs often affect multiple segments of the liver and respond relatively well to partial hepatectomy. 18 However, the definition must rely on a meticulous histopathologic examination or genetic diagnosis by microsatellite loss of heterozygosity in the resected liver tumors. 19, 20 In fact, by clonal analysis using Southern blot hybridization, Hsu et al found unicentric origin IM in 15 of 16 (93.8%) patients with multiple HCCs that were histologically regarded as multicentric in origin. 21 Furthermore, they identified 18 of 99 patients with multiple HCCs, and only 11 patients had undergone multiple-site resection. 18 This means that most of the patients with multiple HCCs may be regarded as having IM, and multicentric HCCs with synchronous occurrence are thought to be clinically less important than those with metachronous occurrence.
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In the present study, we demonstrated that patients with tumor number ≤ 3 and largest tumor size ≤ 5 cm had a better outcome if they initially received hepatectomy than if they underwent nonsurgical multidisciplinary therapy. The Liver Cancer Study Group of Japan, which enrolled 12,888 patients with small-sized HCCs from a nationwide survey of approximately 800 institutes in Japan from 1988 to 1996, reported that patients in clinical stage II with two tumors > 2 cm had higher survival rates following hepatic resection compared with the nonsurgical group. 23 The non-randomized and retrospective nature of both studies may limit interpretation of the results. Nevertheless, hepatectomy usually needs an adequate surgical margin so that invisible micrometastasis, which is often at a distance from the main tumor, may be removed and the frequency of IM reduced. 24, 25 The indications for surgical and nonsurgical modalities remain unclear for MNHCC. To identify which subgroup of patients would benefit the most from surgery, we investigated all the patients who underwent hepatectomy for MNHCC. We found that those with serum AFP > 400 ng/mL, > 3 tumors, tumors with microvascular invasion or tumor size > 5 cm, and those receiving multiple-site hepatic resection had significantly poorer outcome by univariate analysis. Because method and extent of liver resection for the same patient may have varied between different surgeons in the present study, we also investigated the distribution and location of the tumors and categorized them into four types of multinodularity, as depicted in Figure 1 . Those patients with type A tumors had a significantly higher survival rate than those with other types. By multivariate analysis, however, only multiple-site hepatic resection was a significant, independent unfavorable factor, which indicates that patients with MNHCC may benefit from oneblock resection, irrespective of other prognostic factors. We speculate that patients with multiple nodules resulting from IM must have microinvasion among the tumor invading fronts. Lai et al investigated 23 resected HCC tumor specimens (1.7-18.1 cm in diameter) and reported that the distance from the main tumor to the microsatellite site ranged from 0.1 mm to 71 mm. They demonstrated that the presence of a large HCC (≥ 5 cm), multinodular lesions, macroscopic venous tumor thrombus, liver invasion, and non-encapsulated dominant nodules were associated positively with distance from the microsatellite to the main HCC tumor. 26 One-block resection may provide an opportunity for eradicating the tumor cells among the tumor fronts, and thus improve patient survival. In the present study, the 5-year overall survival rate of patients who underwent one-block resection for MNHCC was 35%. For patients with total tumor number ≤ 3 and largest tumor size ≤ 5 cm, those who underwent one-block resection had favorable survival when compared with the nonsurgical group (45.1% and 22.6%, respectively). In contrast, those patients who underwent multiple-site resection had no survival benefit.
One drawback of the present study is that both the surgical and nonsurgical groups were specially selected and may have introduced some bias to the analysis. Furthermore, small satellites are not easy to confirm by imaging, and the nonsurgical group may have had more advanced disease than the hepatectomy group. However, the comparison was made among those with tumor size ≤ 5 cm and tumor number ≤ 3, which were also the selection criteria for liver transplantation. 13 The results of the present study may help us to select treatment modalities for patients who are still on the waiting list. When the tumor size reaches 5 cm or the tumor number increases, the large majority of HCCs will demonstrate microscopic invasion into portal venules or the lymphatics that surround the periphery of the tumor. Liver transplantation is relatively contraindicated. 27 Our results indicate that one-block surgery may provide the best treatment option for such advanced disease.
In conclusion, this study is in line with the report of Ng et al, in which patients with MNHCC benefited from hepatectomy. 28 Although we demonstrated that the outcome of hepatectomy for those with tumor number ≤ 3 and tumor size ≤ 5 cm was superior to that in the nonsurgical group, our analysis also showed that the best survival was achieved with one-block hepatic resection, regardless of tumor number or size. We recommend that hepatectomy should be included in the multidisciplinary therapy for MNHCC, provided that the liver function reserve is acceptable for resection.
